Physician profile
Stephen A Williams
NPI 1437370947
$5,171.40
in general payments reported to CMS, 2019-2025
31 companies · $3,879 in 2025
The $3,879 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.49 · 2020: $121 · 2021: $118 · 2022: $472 · 2023: $478 · 2024: $69.88 · 2025: $3,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,286 · Food and Beverage: $2,047 · Education: $73.72 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,286.09 |
| Food and Beverage | $2,047.30 |
| Education | $73.72 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $3,744.24 | 2025 | |
| Amgen INC. | $165.13 | 2020-2025 | Lumakras, Kyprolis |
| Zimmer Biomet Holdings, INC. | $104.00 | 2022 | |
| Mirati Therapeutics, INC. | $100.67 | 2023 | Krazati |
| Novartis Pharmaceuticals Corporation | $93.30 | 2020-2024 | |
| Pfizer INC. | $88.52 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $68.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $66.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.23 | 2023-2025 | Opdivo |
| Eisai INC. | $56.38 | 2022 | |
| Glaxosmithkline, LLC. | $54.48 | 2020-2023 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $53.81 | 2020-2021 | |
| Genentech USA, INC. | $50.95 | 2023 | Venclexta, Gazyva, Polivy |
| Kite Pharma, INC. | $49.88 | 2021-2022 | |
| Janssen Biotech, INC. | $48.93 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.19 | 2019-2023 | |
| Array Biopharma INC | $36.74 | 2022-2023 | Mektovi, Lorbrena, Braftovi |
| Gilead Sciences, INC. | $28.96 | 2021-2024 | |
| Stemline Therapeutics INC. | $24.68 | 2023 | Orserdu |
| Exelixis INC. | $24.05 | 2022 | |
| Myovant Sciences INC. | $22.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.07 | 2023 | Tagrisso |
| Celgene Corporation | $21.75 | 2023 | Pomalyst |
| Regeneron Healthcare Solutions, INC. | $21.50 | 2022 | |
| Emd Serono, INC. | $20.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.09 | 2023 | |
| Lilly USA, LLC | $18.98 | 2023 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $18.00 | 2025 | Quzyttir |
| Pharmacyclics LLC, An Abbvie Company | $16.56 | 2022 | |
| Spectrum Pharmaceuticals INC. | $15.77 | 2024 | Rolvedon |
| Alnylam Pharmaceuticals INC. | $13.55 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.